Drug Trial Radar · NCT03395080
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Mar 5, 2018
Primary completion
Sep 9, 2020
Study completion Jan 27, 2021
Sponsor
- Lead sponsor
- Leap Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination with Paclitaxel in Patients With Recurrent Epithelial Endometrial Cancer, Epithelial Ovarian Cancer, or Carcinosarcoma
Conditions
- Endometrial Cancer
- Uterine Cancer
- Ovarian Cancer
- Carcinosarcoma
Interventions
PaclitaxelDrug
Administered by IV infusion
300mg DKN-01Drug
Administered by IV infusion
600mg DKN-01Drug
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Objective Response Rate (ORR) in EEC or EOC PatientsTime frame: Baseline to study completion (approximately 6 months)
- Number of Subjects With Objective Response Rate (ORR) in Carcinosarcoma (MMMT) PatientsTime frame: Baseline to study completion (approximately 6 months)
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
HonorHealth
Scottsdale, Arizona
Florida Cancer Specialists & Research Institute
West Palm Beach, Florida
University of Chicago
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
HCA Midwest Health System Clinical Research
Kansas City, Missouri
Cleveland Clinic
Cleveland, Ohio
Ohio State University Wexner Medical Center
Hilliard, Ohio
Stephenson Cancer Center - University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
The University of Tennessee West Cancer Center
Germantown, Tennessee
Tennessee Oncology, PLLC
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
University of Virginia Cancer Center
Charlottesville, Virginia
University of Wisconsin
Madison, Wisconsin
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.